Total Payments
$224,737
2024 Payments
$42,898
Companies
74
Transactions
1,114
Medicare Patients
3,445
Medicare Billing
$657,474
Payment Breakdown by Category
Consulting$111,844 (49.8%)
Other$74,728 (33.3%)
Food & Beverage$18,807 (8.4%)
Travel$14,911 (6.6%)
Research$3,738 (1.7%)
Education$708.20 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $111,844 | 50 | 49.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $59,073 | 20 | 26.3% |
| Food and Beverage | $18,807 | 967 | 8.4% |
| Honoraria | $15,655 | 6 | 7.0% |
| Travel and Lodging | $14,911 | 50 | 6.6% |
| Unspecified | $3,738 | 10 | 1.7% |
| Education | $708.20 | 11 | 0.3% |
Payments by Type
General
$220,999
1,104 transactions
Research
$3,738
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $48,068 | 92 | $0 (2024) |
| GENZYME CORPORATION | $33,749 | 64 | $0 (2024) |
| Secura Bio, Inc. | $15,694 | 8 | $0 (2023) |
| Celgene Corporation | $14,454 | 56 | $0 (2024) |
| AbbVie Inc. | $12,832 | 33 | $0 (2023) |
| Kite Pharma, Inc. | $12,294 | 19 | $0 (2023) |
| PFIZER INC. | $11,947 | 58 | $0 (2024) |
| Gilead Sciences, Inc. | $11,399 | 28 | $0 (2024) |
| Genentech, Inc. | $10,863 | 8 | $0 (2022) |
| Incyte Corporation | $8,374 | 40 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $42,898 | 225 | GENZYME CORPORATION ($17,316) |
| 2023 | $40,094 | 221 | E.R. Squibb & Sons, L.L.C. ($17,203) |
| 2022 | $56,948 | 229 | GENZYME CORPORATION ($15,852) |
| 2021 | $17,926 | 88 | Genentech, Inc. ($3,850) |
| 2020 | $22,835 | 76 | Celgene Corporation ($7,797) |
| 2019 | $27,156 | 160 | AbbVie, Inc. ($6,398) |
| 2018 | $12,364 | 104 | AbbVie, Inc. ($6,348) |
| 2017 | $4,516 | 11 | PFIZER INC. ($4,355) |
All Payment Transactions
1,114 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,030.00 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Oncology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,342.50 | General |
| 12/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $9.63 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Oncology | ||||||
| 12/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $49.95 | General |
| 12/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| 12/04/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | YONSA (Drug), Odomzo | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Oncology | ||||||
| 12/02/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: Oncology | ||||||
| 11/22/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: Oncology | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: Rare Disease | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.30 | General |
| Category: Oncology | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Immunology | ||||||
| 11/15/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BI754111 & BI754091 BI75411 combination | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,996 | 1 |
| A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | Astellas Pharma Global Development | $1,742 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 967 | 2,686 | $637,548 | $181,424 |
| 2022 | 9 | 897 | 2,572 | $580,067 | $157,420 |
| 2021 | 9 | 898 | 2,781 | $638,040 | $177,694 |
| 2020 | 9 | 683 | 2,163 | $537,400 | $140,936 |
Total Patients
3,445
Total Services
10,202
Medicare Billing
$657,474
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 207 | 587 | $213,081 | $59,742 | 28.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 95 | 584 | $200,312 | $59,422 | 29.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 85 | 205 | $49,200 | $13,968 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 61 | 96 | $47,364 | $13,875 | 29.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 82 | 107 | $48,043 | $11,921 | 24.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $21,421 | $5,509 | 25.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 176 | 509 | $7,635 | $4,276 | 56.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 28 | $20,524 | $4,188 | 20.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 174 | 500 | $10,000 | $3,798 | 38.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 18 | 24 | $15,648 | $3,756 | 24.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 11 | 15 | $4,320 | $970.35 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 189 | 561 | $203,643 | $58,032 | 28.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 95 | 587 | $200,655 | $51,331 | 25.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 79 | 104 | $46,696 | $11,815 | 25.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 56 | 75 | $36,525 | $11,110 | 30.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 61 | 145 | $34,320 | $8,845 | 25.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 40 | 40 | $27,640 | $7,641 | 27.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 181 | 517 | $10,340 | $3,967 | 38.4% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 15 | 19 | $12,388 | $3,128 | 25.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 181 | 524 | $7,860 | $1,553 | 19.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 170 | 565 | $205,095 | $61,530 | 30.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 92 | 609 | $208,887 | $54,165 | 25.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 70 | 227 | $54,480 | $14,033 | 25.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 89 | 116 | $52,084 | $13,312 | 25.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 50 | 77 | $37,499 | $12,333 | 32.9% |
About Dr. Mohamad Cherry, MD
Dr. Mohamad Cherry, MD is a Hematology & Oncology healthcare provider based in Morristown, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386690840.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohamad Cherry, MD has received a total of $224,737 in payments from pharmaceutical and medical device companies, with $42,898 received in 2024. These payments were reported across 1,114 transactions from 74 companies. The most common payment nature is "Consulting Fee" ($111,844).
As a Medicare-enrolled provider, Cherry has provided services to 3,445 Medicare beneficiaries, totaling 10,202 services with total Medicare billing of $657,474. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location Morristown, NJ
- Active Since 05/26/2006
- Last Updated 01/11/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1386690840
Products in Payments
- SARCLISA (Biological) $17,814
- ELITEK (Biological) $15,780
- COPIKTRA (Drug) $15,694
- REBLOZYL (Biological) $14,438
- Yescarta (Drug) $9,465
- Venclexta (Drug) $6,413
- TIBSOVO (Drug) $5,614
- MONOFERRIC (Drug) $5,345
- TAZVERIK (Drug) $5,233
- BOSULIF (Drug) $4,042
- BESREMI (Drug) $3,289
- Luspatercept (Drug) $3,263
- ELREXFIO (Drug) $3,049
- MONJUVI (Drug) $2,433
- ONUREG (Drug) $2,156
- VYXEOS (Drug) $2,006
- Tecartus (Drug) $1,700
- TECVAYLI (Biological) $1,432
- XOSPATA (Drug) $1,339
- IMBRUVICA (Drug) $1,257
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Morristown
Charles Farber, M.d, Phd, M.D, PHD
Hematology & Oncology — Payments: $740,251
Hematology & Oncology $740,251
Michael Scola, M.d, M.D
Hematology & Oncology — Payments: $692,337
Hematology & Oncology $692,337
William Derosa, D.o, D.O
Hematology & Oncology — Payments: $74,550
Hematology & Oncology $74,550
Steven Papish, M.d, M.D
Hematology & Oncology — Payments: $58,615
Hematology & Oncology $58,615
Dr. Muhammad Naqvi, M.d, M.D
Hematology & Oncology — Payments: $35,581
Hematology & Oncology $35,581
Dr. Clarissa Geyer, M.d, M.D
Hematology & Oncology — Payments: $9,556
Hematology & Oncology $9,556